X4 Pharmaceuticals Inc (XFOR)

$3.69 -0.19 (-4.90%)
Market Cap 322.64M
Revenue (ttm) 2.56M
Net Income (ttm) -37.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,462.89%
Debt to Equity Ratio 1.23
Volume 216,900
Avg Vol 487,300
Day's Range N/A - N/A
Shares Out 87.44M
Stochastic %K 28%
Beta 0.43
Analysts Strong Sell
Price Target $10.00

Company Profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 529 8300
Address:
61 North Beacon Street, 4th Floor, Boston, United States
Sandeep150
Sandeep150 Mar. 12 at 8:45 PM
$XFOR same there where it started. It dying
0 · Reply
EldarGman
EldarGman Mar. 11 at 3:25 PM
$PAVS short interest- 64,35% of the public float!!!🚀🚀🚀buy and hold!!!💪 $HIMS $ROLR $XFOR
1 · Reply
topstockalerts
topstockalerts Mar. 10 at 7:36 PM
$XFOR biotech traders track around immune therapy program progress. These names often get attention when development milestones approach.
0 · Reply
The_Fudge_ster
The_Fudge_ster Mar. 10 at 7:32 PM
$XFOR what is wrong with this POS? It's going up or something.
0 · Reply
barney00
barney00 Mar. 10 at 2:33 PM
$XFOR seems to be tracking...
1 · Reply
Love_To_Learn
Love_To_Learn Mar. 10 at 2:07 PM
$XFOR $DTIL RAISING U UP
0 · Reply
starkist
starkist Mar. 9 at 4:47 PM
$XFOR in the wholesale produce business when you dealing with a perishable food item thats not holding up (short position) your initial loss is your least expensive!
0 · Reply
notreload_ai
notreload_ai Mar. 9 at 2:57 PM
Guggenheim starts coverage on $XFOR with a Buy rating and $12 price target, highlighting major potential from mavorixafor in rare blood disorders like WHIM syndrome and chronic neutropenia. https://notreload.xyz/guggenheim-rates-xfor-buy-12-target/
0 · Reply
kikis882
kikis882 Mar. 9 at 2:01 PM
$XFOR https://m.au.investing.com/news/analyst-ratings/guggenheim-initiates-x4-pharmaceuticals-stock-with-buy-rating-93CH-4300467?ampMode=1
0 · Reply
islandpunk
islandpunk Mar. 6 at 9:27 PM
$XFOR Morgan Stanley just filed 13G for 10% https://www.sec.gov/Archives/edgar/data/895421/000089542126000094/xslSCHEDULE_13G_X01/primary_doc.xml
0 · Reply
Latest News on XFOR
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

Mar 4, 2026, 7:00 AM EST - 11 days ago

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

Mar 3, 2026, 10:04 AM EST - 12 days ago

X4 Pharmaceuticals: An Undercovered Biotech Trade With A Funded Path To FDA Approval

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 2, 2026, 4:30 PM EST - 13 days ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

Feb 27, 2026, 7:00 AM EST - 16 days ago

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

Feb 16, 2026, 5:57 PM EST - 27 days ago

X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript

X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

Feb 3, 2026, 7:00 AM EST - 5 weeks ago

X4 Pharmaceuticals to Participate in Guggenheim's Emerging Outlook: Biotech Summit 2026

X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia

Dec 1, 2025, 9:09 AM EST - 3 months ago

X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

Nov 5, 2025, 4:01 PM EST - 4 months ago

X4 Pharmaceuticals to Participate in Guggenheim's Second Annual Healthcare Innovation Conference

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 4 months ago

X4 Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

Oct 27, 2025, 7:05 PM EDT - 4 months ago

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

Oct 24, 2025, 12:37 AM EDT - 5 months ago

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Oct 23, 2025, 4:01 PM EDT - 5 months ago

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Sep 17, 2025, 7:00 AM EDT - 6 months ago

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 15, 2025, 4:05 PM EDT - 7 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Aug 13, 2025, 7:00 AM EDT - 7 months ago

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Aug 12, 2025, 7:00 AM EDT - 7 months ago

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Jun 16, 2025, 8:00 AM EDT - 9 months ago

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

Jun 10, 2025, 8:00 AM EDT - 9 months ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025, 4:12 PM EDT - 10 months ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025, 12:44 PM EDT - 11 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025, 6:01 AM EDT - 11 months ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Top 3 Health Care Stocks That May Rocket Higher In April

Apr 28, 2025, 7:16 AM EDT - 11 months ago

Top 3 Health Care Stocks That May Rocket Higher In April

BMY UNH

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

Apr 24, 2025, 8:03 AM EDT - 11 months ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Announces Reverse Stock Split

Apr 24, 2025, 8:00 AM EDT - 11 months ago

X4 Pharmaceuticals Announces Reverse Stock Split

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 3:02 PM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 25, 2025, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Mar 11, 2025, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 19, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Feb 6, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 24, 2025, 7:36 AM EST - 1 year ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Jan 13, 2025, 7:35 AM EST - 1 year ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 9:31 PM EST - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:07 AM EST - 1 year ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Nov 13, 2024, 6:01 AM EST - 1 year ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 9:30 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 8, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jul 2, 2024, 6:17 PM EDT - 1 year ago

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 27, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Jun 24, 2024, 4:51 AM EDT - 1 year ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR VRNA

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 29, 2024, 4:30 PM EDT - 1 year ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 9, 2024, 6:30 AM EDT - 2 years ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 6:01 AM EDT - 2 years ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 30, 2024, 8:00 AM EDT - 2 years ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

Apr 29, 2024, 5:02 PM EDT - 2 years ago

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Apr 29, 2024, 6:37 AM EDT - 2 years ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

Apr 29, 2024, 6:30 AM EDT - 2 years ago

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

Sandeep150
Sandeep150 Mar. 12 at 8:45 PM
$XFOR same there where it started. It dying
0 · Reply
EldarGman
EldarGman Mar. 11 at 3:25 PM
$PAVS short interest- 64,35% of the public float!!!🚀🚀🚀buy and hold!!!💪 $HIMS $ROLR $XFOR
1 · Reply
topstockalerts
topstockalerts Mar. 10 at 7:36 PM
$XFOR biotech traders track around immune therapy program progress. These names often get attention when development milestones approach.
0 · Reply
The_Fudge_ster
The_Fudge_ster Mar. 10 at 7:32 PM
$XFOR what is wrong with this POS? It's going up or something.
0 · Reply
barney00
barney00 Mar. 10 at 2:33 PM
$XFOR seems to be tracking...
1 · Reply
Love_To_Learn
Love_To_Learn Mar. 10 at 2:07 PM
$XFOR $DTIL RAISING U UP
0 · Reply
starkist
starkist Mar. 9 at 4:47 PM
$XFOR in the wholesale produce business when you dealing with a perishable food item thats not holding up (short position) your initial loss is your least expensive!
0 · Reply
notreload_ai
notreload_ai Mar. 9 at 2:57 PM
Guggenheim starts coverage on $XFOR with a Buy rating and $12 price target, highlighting major potential from mavorixafor in rare blood disorders like WHIM syndrome and chronic neutropenia. https://notreload.xyz/guggenheim-rates-xfor-buy-12-target/
0 · Reply
kikis882
kikis882 Mar. 9 at 2:01 PM
$XFOR https://m.au.investing.com/news/analyst-ratings/guggenheim-initiates-x4-pharmaceuticals-stock-with-buy-rating-93CH-4300467?ampMode=1
0 · Reply
islandpunk
islandpunk Mar. 6 at 9:27 PM
$XFOR Morgan Stanley just filed 13G for 10% https://www.sec.gov/Archives/edgar/data/895421/000089542126000094/xslSCHEDULE_13G_X01/primary_doc.xml
0 · Reply
barney00
barney00 Mar. 3 at 5:27 PM
$XFOR hopefully bottomed and will start steadily moving up and to the right…
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 27 at 5:34 PM
$XFOR Current Stock Price: $3.26
0 · Reply
focafoca99
focafoca99 Feb. 27 at 1:51 PM
$XFOR positive opinion received from the EMA! Could be a good day.
0 · Reply
notreload_ai
notreload_ai Feb. 27 at 12:33 PM
$XFOR receives positive CHMP opinion for mavorixafor, the potential first EU therapy for ultra-rare WHIM syndrome. EC decision expected Q2 2026. https://notreload.xyz/x4-mavorixafor-wins-positive-chmp-opinion-for-whim-syndrome/
0 · Reply
TwongStocks
TwongStocks Feb. 27 at 12:07 PM
$XFOR Receives positive CHMP recommendation for approval of Mavorixafor in WHIM Syndrome. https://www.stocktitan.net/news/XFOR/x4-pharmaceuticals-receives-positive-opinion-from-the-ema-chmp-xsy1772e3n6f.html
0 · Reply
StockNews_Live
StockNews_Live Feb. 27 at 12:02 PM
$XFOR X4 Pharmaceuticals announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authoriza…
0 · Reply
Parobull
Parobull Feb. 25 at 6:31 PM
HCWC fundamentals don’t match the price. Real profits, heavy short interest, thin borrow. If buyers step in, that .50s gap could close fast. $CPOP $XFOR $ADIL $CLEU
0 · Reply
Parobull
Parobull Feb. 25 at 2:33 PM
HCWC is the type of setup that turns violent quickly. Profitable microcap, strong cash flow, heavy short positioning, and borrow drying up. The .50s gap is wide open and thin floats don’t grind they expand. Serious squeeze setup. $CPOP $XFOR $ADIL $CLEU l
0 · Reply
809trader
809trader Feb. 18 at 2:38 AM
$XFOR I’m just here waiting on my baby to comeback to daddy. We are almost there baby 🫶
0 · Reply
Parobull
Parobull Feb. 17 at 4:45 AM
All eyes on $OLB tomorrow, almost 1m volume on overnight already, if this gets a 30-50m volume day it can easily fill that .80c gap and see a squeeze towards $1++ $XFOR $BNAI $SUNE $BATL on watch too
0 · Reply
Pangloss_0589
Pangloss_0589 Feb. 16 at 8:00 PM
$XFOR Morgan Stanley filed a 13G with 8.9M shares, over 9% ownership. I must say our institutions ownership is pretty crazy. It’d be nice if things got moving price-wise before 2027…
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 7:28 PM
$XFOR RSI: 43.14, MACD: -0.0935 Vol: 0.16, MA20: 3.67, MA50: 3.81 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply